email article A therapeutic HIVACAT T-cell immunogen (HTI) vaccine regimen was safe, and about 40% of recipients were able to stay off antiretroviral therapy (ART) for several months, a researcher said. In a first-in-human phase I/II randomized trial that began with 45 participants, eight of 20 participants receiving the vaccine successfully went 22 weeks without ART, compared with one who received placebo, reported Beatriz Mothe, MD, of IrsiCaixa Institute for AIDS Research in Badalona, Spain. Moreover, five vaccine participants and one placebo participant maintained viral loads of les...